Abiraterone
- Generic Name
- Abiraterone
- Brand Names
- Yonsa, Zytiga, Abiraterone Krka, Abiraterone Accord, Abiraterone Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C24H31NO
- CAS Number
- 154229-19-3
- Unique Ingredient Identifier
- G819A456D0
- Background
Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis. Abiraterone was first approved by the FDA and EMA on April, July, and September 2011, respectively. It is used to treat metastatic castration-resis...
- Indication
Abiraterone is indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in combination with methylprednisolone or prednisone.
...
- Associated Conditions
- Metastatic Castration Sensitive Prostate Cancer (mCSPC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
- Associated Therapies
- -
AMG 386 and Abiraterone for Advanced Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-03-14
- Last Posted Date
- 2019-03-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 36
- Registration Number
- NCT01553188
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-03-05
- Last Posted Date
- 2019-07-05
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 72
- Registration Number
- NCT01543776
- Locations
- 🇺🇸
Emory University Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Ingalls Memorial Hospital, Harvey, Illinois, United States
🇺🇸Illinois Cancer Care, Peoria, Illinois, United States
A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate
- Conditions
- Interventions
- First Posted Date
- 2012-01-25
- Last Posted Date
- 2022-05-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 32
- Registration Number
- NCT01517802
Cabazitaxel and Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-01-18
- Last Posted Date
- 2016-07-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 38
- Registration Number
- NCT01511536
- Locations
- 🇬🇧
Investigational Site Number 826001, Sutton, United Kingdom
🇺🇸Investigational Site Number 840002, New Haven, Connecticut, United States
🇺🇸Investigational Site Number 840001, San Francisco, California, United States
Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
- First Posted Date
- 2012-01-02
- Last Posted Date
- 2021-05-14
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 32
- Registration Number
- NCT01503229
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
A Study Examining Doses of Abiraterone Acetate in Adult Women With 21-Hydroxylase Deficiency
- First Posted Date
- 2011-12-20
- Last Posted Date
- 2014-02-28
- Target Recruit Count
- 6
- Registration Number
- NCT01495910
Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-12-08
- Last Posted Date
- 2019-03-19
- Lead Sponsor
- Dendreon
- Target Recruit Count
- 69
- Registration Number
- NCT01487863
- Locations
- 🇺🇸
Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States
🇺🇸Moores UCSD Cancer Center, La Jolla, California, United States
🇺🇸UCSD Medical Center - La Jolla, La Jolla, California, United States
Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2011-12-06
- Last Posted Date
- 2023-09-14
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 298
- Registration Number
- NCT01485861
- Locations
- 🇺🇸
HonorHealth Research Institute ? Bisgrove, Scottsdale, Arizona, United States
🇺🇸Kaiser Permanente Medical Ctr, Honolulu, Hawaii, United States
🇨🇿Vseobecna fakultni nemocnice v Praze, Praha 2, Czechia
A Study to Determine the Short-Term Safety of Continuous Dosing of Abiraterone Acetate and Prednisone in Modified Fasting and Fed States to Patients With Metastatic Castration-Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-08-29
- Last Posted Date
- 2014-07-25
- Lead Sponsor
- Janssen-Ortho Inc., Canada
- Target Recruit Count
- 25
- Registration Number
- NCT01424930
Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-07-13
- Last Posted Date
- 2018-03-15
- Lead Sponsor
- Mary-Ellen Taplin, MD
- Target Recruit Count
- 40
- Registration Number
- NCT01393730
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸University of Washington Medical Center, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.